GlycoMimetics (GLYC) investor relations material

Executive summary

• GlycoMimetics ceased development of its drug candidates after negative Phase 3 and Phase 2 trial results for uproleselan in AML, with no statistically significant benefit observed and no ongoing clinical trials as of March 31, 2025.

• The company initiated a strategic review, reduced its workforce by 80%, and entered into a merger agreement with Crescent Biopharma, expected to close in Q2 2025, after which Crescent's business will become primary.

• A $200 million private placement is planned to close concurrently with the merger, with pre-merger GlycoMimetics shareholders expected to own only 2.6% of the combined company post-transaction.

Financial highlights

• Net loss for Q1 2025 was $2.34 million, a significant improvement from a $10.74 million net loss in Q1 2024, reflecting the wind-down of operations.

• Research and development expenses dropped to $15,000 in Q1 2025 from $6.03 million in Q1 2024; general and administrative expenses fell to $2.38 million from $5.09 million year-over-year.

• Cash and cash equivalents were $5.6 million as of March 31, 2025, down from $10.7 million at year-end 2024.

• Net cash used in operating activities was $5.1 million in Q1 2025, down from $10.5 million in Q1 2024.

• No revenue was recognized in Q1 2025; the Apollomics license agreement was terminated effective May 21, 2025.

Outlook and guidance

• Current cash is expected to fund operations until the merger closes; if the merger and private placement do not close by Q3 2025, the company may seek other alternatives or liquidate.

• No plans to continue development of uproleselan or other drug candidates; Crescent Biopharma's pipeline will become the focus post-merger.